enGene Holdings (ENGN)
NASDAQ:ENGN
Want to see ENGN full AI Analyst Report?
ENGN Stock Chart & Stats
$8.07
$0.17(2.19%)
At close: 4:00 PM EST
$8.07
$0.17(2.19%)
Day’s Range― - ―
52-Week Range$2.65 - $12.25
Previous CloseN/A
Volume16.79K
Average Volume (3M)473.44K
Market Cap
$535.25M
Enterprise Value$405.90M
Total Cash (Recent Filing)$275.95M
Total Debt (Recent Filing)$33.46M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Jun 12, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding66,989,460
10 Day Avg. Volume266,560
30 Day Avg. Volume473,435
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.15K
Enterprise Value/Ebitda-3.41
Forecast
1Y Price Target
$24.00Price Target Upside197.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And TolerabilityDetalimogene voraplasmid has demonstrated promising efficacy and a favorable tolerability profile with low treatment interruptions in trials, supporting competitive clinical positioning.
Ease Of Adoption In Community PracticeSimple storage, straightforward administration, and compatibility with standard buy-and-bill processes align the therapy with community urology clinic workflows and could drive rapid adoption.
Regulatory And Data CatalystsSelection for the FDA CMC Development and Readiness Pilot program and pivotal cohort data updates could validate regulatory alignment and provide a larger dataset to support investor confidence if response rates remain consistent.
Bears Say
Competitive Landscape ConstraintsA crowded field of similar therapies could limit the company's ability to secure a dominant market position and restrict potential commercial share.
Durability UncertaintyUncertainty about long-term durability of response remains because later data will emphasize sustained outcomes and current follow-up may not fully capture longer-term results.
Financial Pressure From Development And LaunchAnalyst's neutral stance with a reduced valuation reflects higher operating costs from the pivotal trial and expected launch expenses that could pressure financial outlooks.
enGene Holdings News
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $2.65 and its highest was $12.25 in the past 12 months.
What is enGene Holdings’s market cap?
enGene Holdings’s market cap is $535.25M.
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Jun 12, 2026 which is in 45 days.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Mar 09, 2026. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.56 by $0.12.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings pays a Quarterly dividend of $0.13 which represents an annual dividend yield of N/A. See more information on enGene Holdings dividends here
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate is -0.47.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 66,989,460 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.56. Following the earnings report the stock price went down -18.779%.
Which hedge fund is a major shareholder of enGene Holdings?
Currently, no hedge funds are holding shares in ENGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
enGene Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (197.40% Upside)
$24.00 (197.40% Upside)
Blogger Sentiment
Bullish
ENGN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 4.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
101.75%
12-Months-Change
Fundamentals
Return on Equity
-55.83%
Trailing 12-Months
Asset Growth
17.90%
Trailing 12-Months
Company Description
enGene Holdings
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
ENGN Stock 12 Month Forecast
Average Price Target
$24.00
▲(197.40% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Replimune Group
―
Immuneering
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
4.47%
Insiders
2.15% Mutual Funds
― Other Institutional Investors
93.29% Public Companies and
Individual Investors